Publications

• XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.
  Oncoimmunology Volume: 14 Page(s): 2475620
  12/01/2025 Authors: Phillips MJ; Alese OB; Horvat NK; Greene E; Gbolahan OB; Coleman K; Doxie DB; Parihar V; Mahdi ZK; McCook-Veal A
• Rapid Modulation of Circulating Adipokines and Inflammatory Cytokines in Localized Prostate Cancer Following Short-Term Leuprolide Therapy.
  Clin Genitourin Cancer Volume: 23 Page(s): 102358
  04/14/2025 Authors: Yadalam AK; Chaudagar K; Mumme H; Bhasin M; Talekar GR; Waller EK; Lesinski GB; Patel SA; Mandawat A
• Combination radiation and PD-L1 enhance tumor control by stimulating CD8+PD-1+TCF-1+T cells in the tumor-draining lymph node.
  Nat Commun Volume: 16 Page(s): 3522
  04/14/2025 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N
• Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.
  Cell Rep Med Volume: 6 Page(s): 101881
  01/21/2025 Authors: Nagaraju GP; Saddala MS; Foote JB; Khaliq AM; Masood A; Golivi Y; Bandi DSR; Sarvesh S; Reddy SP; Switchenko J
• Muc16CD is a novel CAR Tcell target antigen for the treatment of pancreatic cancer.
  Mol Ther Oncol Volume: 32 Page(s): 200868
  12/19/2024 Authors: Lin HK; Blake DA; Liu T; Freeman R; Lesinski GB; Yang L; Rafiq S
• A pilot study of the immune microenvironment of GI neuroendocrine carcinoma.
  Endocr Relat Cancer Volume: 31
  10/01/2024 Authors: McDonald A; Avadhani V; Oprea-Ilies G; Zakka K; Lesinski GB; Gbolahan OB; Alese O
• VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer.
  Cancer Res Volume: 84 Page(s): 2954 - 2967
  09/16/2024 Authors: Passang T; Wang S; Zhang H; Zeng F; Hsu P-C; Wang W; Li J-M; Liu Y; Ravindranathan S; Lesinski GB
• Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
  J Immunother Cancer Volume: 12
  06/30/2024 Authors: Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
• Diagnostic and Prognostic Biomarkers of Chronic Pancreatitis: A Conceptual Framework Based on the PRoBE Design.
  Gastroenterology Volume: 166 Page(s): 957 - 962.e3
  06/01/2024 Authors: Yadav D; Conwell DL; Pandol SJ; Steen H; Feng Z; Li L; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
• Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
  J Exp Clin Cancer Res Volume: 43 Page(s): 76
  03/12/2024 Authors: Yang F; Yuan C; Chen F; Qin ZS; Schmitt NC; Lesinski GB; Saba NF; Teng Y
• Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node.
  Res Sq
  03/06/2024 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N
• Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
  J Immunother Cancer Volume: 12
  01/08/2024 Authors: Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM
• Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3K Blockade Improves Metabolism and Antitumor Immunity.
  Cancer Res Volume: 84 Page(s): 69 - 83
  01/02/2024 Authors: Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy BA; Cole AC; Wyatt MM; Kumaresan S; Thaxton JE; Lesinski GB
• Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
  bioRxiv
  12/18/2023 Authors: Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
• Top advances of the year: Pancreatic cancer.
  Cancer Volume: 129 Page(s): 3843 - 3851
  12/15/2023 Authors: Warren EAK; Lesinski GB; Maithel SK
• Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
  Nature Volume: 623 Page(s): 1034 - 1043
  11/01/2023 Authors: Fan H; Xia S; Xiang J; Li Y; Ross MO; Lim SA; Yang F; Tu J; Xie L; Dougherty U
• Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
  J Immunother Cancer Volume: 11
  10/01/2023 Authors: Akce M; Farran B; Switchenko JM; Rupji M; Kang S; Khalil L; Ruggieri-Joyce A; Olson B; Shaib WL; Wu C
• Impact of nodal status in determining multimodal treatment strategies in non-cardia gastric cancer.
  J Surg Oncol Volume: 128 Page(s): 242 - 253
  08/01/2023 Authors: Ajay PS; Sok CP; Goyal S; Switchenko JM; Maegawa FB; Gillespie TW; Paulos CM; Lesinski GB; Kooby DA; Kennedy TJ
• Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
  J Transl Med Volume: 21 Page(s): 488
  07/20/2023 Authors: Ascierto PA; Avallone A; Bifulco C; Bracarda S; Brody JD; Emens LA; Ferris RL; Formenti SC; Hamid O; Johnson DB
• Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
  Mol Ther Volume: 31 Page(s): 2120 - 2131
  07/05/2023 Authors: Wyatt MM; Huff LW; Nelson MH; Neal LR; Medvec AR; Rangel Rivera GO; Smith AS; Rivera Reyes AM; Knochelmann HM; Riley JL
• Short-Term Soy Bread Intervention Leads to a Dose-Response Increase in Urinary Isoflavone Metabolites and Satiety in Chronic Pancreatitis.
  Foods Volume: 12
  04/24/2023 Authors: Ahn-Jarvis JH; Sosh D; Lombardo E; Lesinski GB; Conwell DL; Hart PA; Vodovotz Y
• Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner.
  JCI Insight Volume: 8
  04/24/2023 Authors: Ware MB; Phillips M; McQuinn C; Zaidi MY; Knochelmann HM; Greene E; Robinson B; Herting CJ; Mace TA; Chen Z
• The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner.
  bioRxiv
  03/10/2023 Authors: Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy A; Cole AC; Wyatt MM; Thaxton JE; Lesinski GB; Paulos CM
• Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
  J Immunother Cancer Volume: 11
  01/01/2023 Authors: Kansal V; Burnham AJ; Kinney BLC; Saba NF; Paulos C; Lesinski GB; Buchwald ZS; Schmitt NC
• The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial.
  Pancreatology Volume: 23 Page(s): 42 - 47
  01/01/2023 Authors: Han S; Conwell DL; Li L; Cervantes A; Hart PA; Cruz-Monserrate Z; Hao W; Lesinski GB; Mace T; Palermo TM
• Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells.
  J Clin Invest Volume: 132
  12/01/2022 Authors: Horvat NK; Lesinski GB
• THE ROLE OF CD26 IN PANCREATIC DUCTAL ADENOCARCINOMA
  Volume: 10 Page(s): A1516 - A1516
  11/01/2022 Authors: Ware B; Hammons J; Karpovsky I; Wyatt M; Mace T; Maithel S; El-Rayes B; Paulos C; Lesinski G; Phillips M
• MULTIPLEXED ION BEAM IMAGING (MIBI) UNCOVERS ADAPTIVE IMMUNE RESPONSES ASSOCIATED WITH CLINICAL OUTCOMES IN ORAL CAVITY SQUAMOUS CELL CARCINOMA TREATED WITH NEOADJUVANT PD-1 INHIBITOR
  Volume: 10 Page(s): A97 - A97
  11/01/2022 Authors: Padmanabhan R; Knochelmann H; Hav M; Nagy M; Si P; Bajaj S; Lesinski G; Neskey D; Paulos C
• STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer.
  Life Sci Alliance Volume: 5
  11/01/2022 Authors: Lefler JE; MarElia-Bennett CB; Thies KA; Hildreth BE; Sharma SM; Pitarresi JR; Han L; Everett C; Koivisto C; Cuitino MC
• Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
  Nat Commun Volume: 13 Page(s): 6418
  10/27/2022 Authors: Ravindranathan S; Passang T; Li J-M; Wang S; Dhamsania R; Ware MB; Zaidi MY; Zhu J; Cardenas M; Liu Y
• Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
  Clin Cancer Res Volume: 28 Page(s): 4336 - 4345
  10/03/2022 Authors: Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK
• GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.
  Gut Volume: 71 Page(s): 1386 - 1398
  07/01/2022 Authors: Ruffolo LI; Jackson KM; Kuhlers PC; Dale BS; Figueroa Guilliani NM; Ullman NA; Burchard PR; Qin SS; Juviler PG; Keilson JM
• Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
  JCO Precis Oncol Volume: 6 Page(s): e2100510
  06/01/2022 Authors: Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ
• High-risk Gene Expression in Colorectal Liver Metastases: Potential for Novel Therapies
  Volume: 29 Page(s): 381 - 381
  05/01/2022 Authors: Medin CR; Turgeon M; Keilson J; Dwivedi B; Herting C; Maithel S; Lesinski GB
• galectin-9 Expression and Decreased Survival in Advanced Biliary Tract Cancers
  Volume: 29 Page(s): 388 - 388
  05/01/2022 Authors: Keilson JM; Ruggieri A; Hammons J; Chen H; Sharon E; Yarchoan M; Azad N; Medin C; Henry C; Robinson B
• Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
  Virol J Volume: 19 Page(s): 32
  02/23/2022 Authors: Tang S; Shi L; Luker BT; Mickler C; Suresh B; Lesinski GB; Fan D; Liu Y; Luo M
• Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
  J Clin Invest Volume: 131
  12/15/2021 Authors: Yarchoan M; Cope L; Ruggieri AN; Anders RA; Noonan AM; Goff LW; Goyal L; Lacy J; Li D; Patel AK
• REPURPOSING CD26 (DPP4) INHIBITORS TO ENHANCE IMMUNOTHERAPY RESPONSE IN PANCREATIC DUCTAL ADENOCARCINOMA
  Volume: 9 Page(s): A948 - A949
  11/01/2021 Authors: Phillips M; Ware M; Herting C; Mace T; Maithel S; Sarmiento J; El-Rayes B; Paulos C; Wyatt M; Lesinski G
• CORRELATIVE ANALYSIS OF BLOOD AND BIOPSY SAMPLES FROM A CLINICAL TRIAL OF HSP90 INHIBITION IN COMBINATION WITH PEMBROLIZUMAB REVEALS INCREASED INTRATUMORAL MYELOID CELL ACCUMULATION AFTER TREATMENT
  Volume: 9 Page(s): A434 - A434
  11/01/2021 Authors: Herting C; Zhang Y; Doxie D; Ware M; Alese O; Wu C; Akce M; Zaidi M; Ruggieri A; Dhodapkar M
• SYSTEMIC IMMUNE PROFILING OF ADVANCED BILIARY TRACT CANCER PATIENTS DEFINES ALTERED CYTOKINES AND IMMUNE CELL POPULATIONS
  Volume: 9 Page(s): A20 - A20
  11/01/2021 Authors: Ruggieri A; Yarchoan M; Liu Y; Goyal S; Sharon E; Chen H; Olson B; Maithel S; El-Rayes B; Azad N
• TARGETING VASOACTIVE INTESTINAL PEPTIDE RECEPTOR SIGNALING IN PANCREATIC DUCTAL ADENOCARCINOMA FOR ENHANCED ANTI-TUMOR RESPONSE TO CHECKPOINT BLOCKADE
  Volume: 9 Page(s): A779 - A781
  11/01/2021 Authors: Ravindranathan S; Fnu TP; Li JM; Dhamsania R; Ware M; Zaidi M; Wang S; Zhu J; Cardenas M; Liu Y
• A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
  Cancer Immunol Immunother Volume: 70 Page(s): 3337 - 3348
  11/01/2021 Authors: Herting CJ; Farren MR; Tong Y; Liu Z; O'Neil B; Bekaii-Saab T; Noonan A; McQuinn C; Mace TA; Shaib W
• Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy.
  Cancer Immunol Res Volume: 9 Page(s): 1187 - 1201
  10/01/2021 Authors: Dennison L; Ruggieri A; Mohan A; Leatherman J; Cruz K; Woolman S; Azad N; Lesinski GB; Jaffee EM; Yarchoan M
• The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
  Cancer Metastasis Rev Volume: 40 Page(s): 675 - 689
  09/01/2021 Authors: Herting CJ; Karpovsky I; Lesinski GB
• Crosstalk Between Cancer Associated Fibroblast Soluble Mediators and Pancreatic Cancer Cells Facilitate an Invasive Phenotype
  Volume: 50 Page(s): 1061 - 1061
  08/01/2021 Authors: Greene E; Ware M; Herting C; Maithel S; Sarmiento J; El-Rayes BF; Tucker-Burden C; Marcus A; Lesinski GB
• Vasoactive Intestinal Peptide Receptor Signaling: A Novel and Targetable Immune Checkpoint Pathway in Pancreatic Cancer
  Volume: 50 Page(s): 1091 - 1092
  08/01/2021 Authors: Ravindranathan S; Tenzin P; Ware M; Zaidi M; Wang S; Dhamsania R; Zhu J; Liu Y; Liu Y; Gumber S
• Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer.
  Ann Surg Oncol Volume: 28 Page(s): 4098 - 4099
  08/01/2021 Authors: Rossi AJ; Khan TM; Hong H; Lesinski GB; Wu C; Hernandez JM
• Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
  Oncologist Volume: 26 Page(s): 668 - 675
  08/01/2021 Authors: Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A
• Delayed Processing of Secretin-Induced Pancreas Fluid Influences the Quality and Integrity of Proteins and Nucleic Acids.
  Pancreas Volume: 50 Page(s): 17 - 28
  01/01/2021 Authors: Cruz-Monserrate Z; Gumpper K; Kaul S; Badi N; Terhorst S; Dubay K; Lesinski GB; Fisher W; McElhany A; Lara LF
• Braking the cell's cycle and invigorating T-cell immunity against pancreatic cancer.
  Gut Volume: 70 Page(s): 4 - 5
  01/01/2021 Authors: Lesinski GB
• Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
  Mol Cancer Ther Volume: 20 Page(s): 150 - 160
  01/01/2021 Authors: Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z
• Lymph Node Subcapsular Sinus Microenvironment-On-A-ChipModeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing.
  iScience Volume: 23 Page(s): 101751
  11/20/2020 Authors: Birmingham KG; O'Melia MJ; Bordy S; Reyes Aguilar D; El-Reyas B; Lesinski G; Thomas SN
• IL-6 IS CRITICAL FOR MEMORY RESPONSES ELICITED BY TH17 CELLS TO TUMORS
  Volume: 8 Page(s): A72 - A73
  11/01/2020 Authors: Knochelmann H; Dwyer C; Smith A; Wyatt M; RIvera GR; Lesinski G; Li Z; Rubinstein M; Paulos C
• INVESTIGATING THE CLINICAL SAFETY, EFFICACY, AND IMMUNE MODULATION OF COMBINED XL888 AND PEMBROLIZUMAB IN METASTATIC GASTROINTESTINAL MALIGNANCIES
  Volume: 8 Page(s): A202 - A203
  11/01/2020 Authors: Herting C; Zhang Y; Doxie D; Farren M; Ware M; Alese O; Wu C; Shaib W; Akce M; Zaidi M
• Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease.
  Br J Cancer Volume: 123 Page(s): 1377 - 1386
  10/01/2020 Authors: Ware MB; Zaidi MY; Yang J; Turgeon MK; Krasinskas A; Mace TA; Keenan K; Farren MR; Ruggieri AN; Li Y
• IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.
  Cancer Res Volume: 80 Page(s): 3920 - 3932
  09/15/2020 Authors: Knochelmann HM; Dwyer CJ; Smith AS; Bowers JS; Wyatt MM; Nelson MH; Rangel Rivera GO; Horton JD; Krieg C; Armeson K
• Turning up the heat on pancreatic ductal adenocarcinoma via inhibiting vasoactive intestinal peptide signaling
  Volume: 80
  08/01/2020 Authors: Ravindranathan S; Ware B; Zaidi M; Zhu J; Dhamsania RK; Wang S; Li Y; Rao IH; Thomas SN; Lesinski GB
• Small slide, big world: Fast detection of altered proteins and RNA levels in clinical samples using Nanostring nCounter (R) GeoMx (TM) Digital Spatial Profiler
  Volume: 80
  08/01/2020 Authors: Gong J; Farren MR; Shaib W; Lesinski G; Warren S; Liang Y
• Effects of cetuximab and CD-3379 on cytokine/chemokine balance in the tumor micro-environment (TME) of squamous cell carcinoma of the head and neck (SCCHN)
  Volume: 80
  08/01/2020 Authors: Wang D; Nannapaneni S; Lesinski GB; Shin DM; Saba NF; Chen GZ
• Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.
  J Immunother Cancer Volume: 8
  08/01/2020 Authors: Ware MB; El-Rayes BF; Lesinski GB
• Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
  Cancer Volume: 126 Page(s): 3360 - 3371
  07/15/2020 Authors: Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
• Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency.
  Biomacromolecules Volume: 21 Page(s): 2635 - 2644
  07/13/2020 Authors: Perdue LA; Do P; David C; Chyong A; Kellner AV; Ruggieri A; Kim HR; Salaita K; Lesinski GB; Porter CC
• Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study.
  Pancreatology Volume: 20 Page(s): 852 - 859
  07/01/2020 Authors: Ahn-Jarvis J; Lombardo E; Cruz-Monserrate Z; Badi N; Crowe O; Kaul S; Komar H; Krishna SG; Lesinski GB; Mace TA
• Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors
  Volume: 26 Page(s): 37 - 37
  06/01/2020 Authors: Evans EE; Lesinski GB; Fisher TL; Mallow C; Olson B; Clavijo PE; Leonard JE; Pastore DR; Smith ES; Zauderer M
• Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs.
  JCO Oncol Pract Volume: 16 Page(s): 319 - 325
  06/01/2020 Authors: Sahin IH; Kane SR; Brutcher E; Guadagno J; Smith KE; Wu C; Lesinski GB; Gunthel CJ; El-Rayes BF
• Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
  Volume: 38
  05/20/2020 Authors: Lowe MC; Olson B; Martinez A; Hammons J; Delman KA; Yushak ML; Allor M; Reilly CA; Mallow CL; Evans EE
• Chemical modification strategies for photo-induced control of immune cell signaling
  Volume: 204
  05/01/2020 Authors: Perdue LA; Do P; Chyong A; Costanza E; Kim HR; David C; Kellner A; Salaita K; Lesinski G; Porter CC
• Photo-regulated control of cytokine signaling via bioinspired, polymer-induced latency
  Volume: 204
  05/01/2020 Authors: Dreaden EC; Perdue LA; Do P; Chyong A; Salaita K; Lesinski G; Porter CC
• IL-6 fuels durable memory for Th17 cell-mediated responses to tumors
  Volume: 204
  05/01/2020 Authors: Knochelmann H; Dwyer C; Smith AS; Wyatt M; Rivera GR; Lesinski G; Li Z; Rubinstein M; Paulos CM
• Integrated Biomarker Study of Pepinemab in Combination with Nivolumab or Ipilimumab to Evaluate Immune Cell Composition of TME in Patients with Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
  Volume: 106 Page(s): 1175 - 1175
  04/01/2020 Authors: Steuer C; Lesinski GB; Evans EE; Fisher TL; Mallow C; Olson B; Pastore DR; Leonard JE; Smith E; Zauderer M
• Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts)
  Volume: 38
  02/01/2020 Authors: Sahin IH; Goyal S; Pumpalova YS; Sonbol MB; Das S; Haraldsdottir S; Chen Z; Akce M; Alese OB; Shaib WL
• Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
  JCI Insight Volume: 5
  01/16/2020 Authors: Farren MR; Sayegh L; Ware MB; Chen H-R; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM
• Diagnosis and Staging of Pancreatic Cancer
  Page(s): 158 - 168
  01/01/2020 Authors: Mulki R; Mekaroonkamol P; Lopez-Aguiar AG; Lesinski GB; Kooby DA; Akce M; Maithel SK; Willingham FF
• Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma
  Volume: 79
  12/01/2019 Authors: Ruffolo LI; Jackson KM; Ullman N; Chacon A; Melucci A; Burchard P; Georger M; Jewell R; Prieto P; Belt B
• Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms
  Volume: 79
  12/01/2019 Authors: Ware MB; Yue J; El-Rayes B; Maithel SK; Sarmiento J; Lesinski GB
• IL-6 regulates CTLA4 expression on CD4+T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma
  Volume: 79
  12/01/2019 Authors: Ware MB; McQuinn C; Mace TA; Bowers J; Shakya R; Farris B; Young G; Carson WE; Paulos CM; El-Rayes B
• Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.
  Mol Cancer Res Volume: 17 Page(s): 2395 - 2409
  12/01/2019 Authors: Chandrasekaran S; Sasaki M; Scharer CD; Kissick HT; Patterson DG; Magliocca KR; Seykora JT; Sapkota B; Gutman DA; Cooper LA
• Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma
  Volume: 7
  11/06/2019 Authors: Ravindranathan S; Wang S; Ware B; Zaidi M; Zhu J; Dhamsania R; Thomas S; Li Y; El-rayes B; Lesinski G
• Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
  Br J Cancer Volume: 121 Page(s): 809 - 818
  11/01/2019 Authors: Sahin IH; Akce M; Alese O; Shaib W; Lesinski GB; El-Rayes B; Wu C
• Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
  Int J Cancer Volume: 145 Page(s): 1529 - 1537
  09/15/2019 Authors: Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
• Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.
  Head Neck Pathol Volume: 13 Page(s): 304 - 312
  09/01/2019 Authors: Lesinski GB; Nannapaneni S; Griffith CC; Patel M; Chen W; Chen Z; Ahmed R; Wieland A; Shin DM; Chen ZG
• Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced -TrCP degradation.
  Oncogene Volume: 38 Page(s): 6270 - 6282
  08/01/2019 Authors: Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun S-Y
• BBI-608 enhances the activity of chemoradiotherapy in colorectal cancer pre-clinical models
  Volume: 79
  07/01/2019 Authors: Nagaraju GP; Balney R; Bethi SR; Govardhanagiri S; Lesinski GBLB; El-Rayes BF
• BBI-608 modulates stemness, angiogenesis and enhances the efficacy of chemoradiotherapy in preclinical models of pancreatic cancer
  Volume: 79
  07/01/2019 Authors: Nagaraju GP; Farren MR; Govardhanagiri S; Bethi SR; Farran B; Lesinski GB; El-Reyes BF
• MEK inhibitors limit inflammatory cytokine production and modulate the immune response in the setting of Cholangiocarcinoma.
  Volume: 79
  07/01/2019 Authors: Ruggieri AN; Farren MR; Yarchoan M; Azad NS; Dennison L; El-Reyes B; Lesinski GB
• BBI-608 modulates DNA repair pathways, induces apoptosis and impacts response to 5-Fluorouracil and ionizing radiation in pancreatic cancer cells
  Volume: 79
  07/01/2019 Authors: Farran B; Nagaraju GP; Shipra SG; Bethi SR; Lesinski GB; El-Rayes B
• Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer
  Volume: 79
  07/01/2019 Authors: Zaidi M; Zhang Y; Ware MB; Farren MR; Komar H; Olson B; Nagaraju GP; Akce M; Alese O; Maithel S
• Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX plus stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment
  Volume: 79
  07/01/2019 Authors: Farren MR; Shaib W; Zaidi M; Sayegh L; Kooby D; Maithel S; Krasinskas A; Alese O; Sarmiento J; El-Rayes B
• Targeting vasoactive intestinal peptide signaling to enhance pancreatic cancer responsiveness to immunotherapy
  Volume: 79
  07/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi MY; Lesinski GB; El-Rayes B; Waller EK
• Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
  Volume: 79
  07/01/2019 Authors: Lesinski GB; Fisher TL; Evans EE; Leonard JE; Pastore DR; Mallow C; Smith E; Zauderer M; Steuer C; Saba NF
• Personalized T cell therapy for metastatic colon cancer.
  Volume: 37
  05/20/2019 Authors: Ravindranathan S; Jajja MR; Waller A; Bommireddy R; Petersen C; Selvaraj P; Yang L; Lesinski GB; El-Rayes BF; Flynn B
• Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
  Volume: 37
  05/20/2019 Authors: Lowe MC; Lesinski GB; Delman KA; Yushak ML; Evans EE; Fisher TL; Kudchadkar RR
• Vasoactive intestinal peptide signaling - a novel immune checkpoint in pancreatic ductal adenocarcinoma
  Volume: 202
  05/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi M; Lesinski GB; El-Rayes B; Waller EK
• Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.
  Sci Rep Volume: 9 Page(s): 5068
  03/25/2019 Authors: Mace TA; Ware MB; King SA; Loftus S; Farren MR; McMichael E; Scoville S; Geraghty C; Young G; Carson WE
• MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
  PLoS One Volume: 14 Page(s): e0224600
  01/01/2019 Authors: Yarchoan M; Mohan AA; Dennison L; Vithayathil T; Ruggieri A; Lesinski GB; Armstrong TD; Azad NS; Jaffee EM
• Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.
  Pancreatology Volume: 19 Page(s): 80 - 87
  01/01/2019 Authors: Ramsey ML; Talbert E; Ahn D; Bekaii-Saab T; Badi N; Bloomston PM; Conwell DL; Cruz-Monserrate Z; Dillhoff M; Farren MR
• The Effects of Pancreas Fluid (PF) Processing on the Quality and Integrity of Proteins, and Nucleic Acids: A Report From the Biospecimen Committee of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
  Volume: 47 Page(s): 1381 - 1382
  11/01/2018 Authors: Cruz-Monserrate Z; Lesinski GB; Fisher WE; Lara LF; Topazian M; Badi N; Kaul S; McElhany A; Orr R; Yadav D
• Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells.
  Ann Pancreat Cancer Volume: 1
  10/01/2018 Authors: Lesinski GB
• Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth.
  Life Sci Alliance Volume: 1 Page(s): e201800190
  10/01/2018 Authors: Pitarresi JR; Liu X; Avendano A; Thies KA; Sizemore GM; Hammer AM; Hildreth BE; Wang DJ; Steck SA; Donohue S
• Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy
  Volume: 78
  07/01/2018 Authors: Evans EE; Bussler H; Mallow C; Reilly C; Torno S; Scrivens M; Howell A; Balch L; Leonard JE; Fisher T
• Altering the cytokine profile in the pancreatic cancer microenvironment with heat shock protein-90 inhibitors to enhance immunotherapy.
  Volume: 200
  05/01/2018 Authors: Lesinski GB; Zhang Y; Farren MR; Komar H; Ware B; Olson B; Zaidi M; Nagaraju GP; Akce M; Alese OB
• Soy-enriched diet limits tumor progression and reduces myeloid derived suppressor cells in the murine TRAMP model of prostate cancer.
  Volume: 200
  05/01/2018 Authors: Mace TA; Loftus S; King S; Young G; Geraghy C; Fareen MR; Ware B; Olson B; Thomas-Ahner J; Clinton SK
• Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-nave pancreatic cancer patients.
  J Cachexia Sarcopenia Muscle Volume: 9 Page(s): 358 - 368
  04/01/2018 Authors: Talbert EE; Lewis HL; Farren MR; Ramsey ML; Chakedis JM; Rajasekera P; Haverick E; Sarna A; Bloomston M; Pawlik TM
• Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.
  Volume: 36
  02/01/2018 Authors: Akce M; Alese OB; Shaib WL; Wu CS-Y; Lesinski GB; El-Rayes BF
• IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
  Volume: 67 Page(s): 320 - 332
  02/01/2018 Authors: Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G
• Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.
  J Clin Pharmacol Volume: 58 Page(s): 7 - 24
  01/01/2018 Authors: Kersh AE; Ng S; Chang YM; Sasaki M; Thomas SN; Kissick HT; Lesinski GB; Kudchadkar RR; Waller EK; Pollack BP
• The Potential of CAR T Cell Therapy in Pancreatic Cancer.
  Front Immunol Volume: 9 Page(s): 2166
  01/01/2018 Authors: Akce M; Zaidi MY; Waller EK; El-Rayes BF; Lesinski GB
• Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.
  Pancreas Volume: 47 Page(s): 1213 - 1221
  01/01/2018 Authors: Fisher WE; Cruz-Monserrate Z; McElhany AL; Lesinski GB; Hart PA; Ghosh R; Van Buren G; Fishman DS; Rinaudo JAS; Serrano J
• Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
  Cancer Volume: 123 Page(s): 4924 - 4933
  12/15/2017 Authors: Belalcazar A; Shaib WL; Farren MR; Zhang C; Chen Z; Yang L; Lesinski GB; El-Rayes BF; Nagaraju GP
• Combined IL-6 and CTLA4 blockade enhances CD8+T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models
  Volume: 5
  11/07/2017 Authors: McQuinn C; Farren M; Mace T; Bowers J; Shakya R; Ferris AB; Young G; Carson W; Paulos C; El-Rayes B
• Assessment of Plasma Interleukin-6 as a Biomarker of Pancreatic Cancer-Induced Cachexia
  Volume: 46 Page(s): 1428 - 1428
  11/01/2017 Authors: Ramsey ML; Talbert E; Conwell DL; Ahn D; Farren MR; Hinton A; Dillhoff M; Krishna SG; Lesinski GB; Manilchuk A
• Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis.
  Pancreas Volume: 46 Page(s): 986 - 993
  09/01/2017 Authors: Komar HM; Hart PA; Cruz-Monserrate Z; Conwell DL; Lesinski GB
• Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
  Cancer Lett Volume: 402 Page(s): 110 - 116
  08/28/2017 Authors: Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
• Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
  Cancer Res Volume: 77 Page(s): 2647 - 2660
  05/15/2017 Authors: Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y
• Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo.
  Sci Rep Volume: 7 Page(s): 1787
  05/11/2017 Authors: Komar HM; Serpa G; Kerscher C; Schwoegl E; Mace TA; Jin M; Yang M-C; Chen C-S; Bloomston M; Ostrowski MC
• Mathematical model of chronic pancreatitis.
  Proc Natl Acad Sci U S A Volume: 114 Page(s): 5011 - 5016
  05/09/2017 Authors: Hao W; Komar HM; Hart PA; Conwell DL; Lesinski GB; Friedman A
• Soy isoflavones and their metabolites modulate cytokine-induced NK cell function.
  Volume: 198
  05/01/2017 Authors: Mace TA; King S; Loftus S; Farren MR; McMichael E; Young G; Carson WE; Clinton SK; Lesinski GB
• Signaling pathways as therapeutic targets in biliary tract cancer.
  Expert Opin Ther Targets Volume: 21 Page(s): 485 - 498
  05/01/2017 Authors: Yang J; Farren MR; Ahn D; Bekaii-Saab T; Lesinski GB
• Laser Capture Microdissection of Pancreatic Acinar Cells to Identify Proteomic Alterations in a Murine Model of Caerulein-Induced Pancreatitis.
  Clin Transl Gastroenterol Volume: 8 Page(s): e89
  04/13/2017 Authors: Shapiro JP; Komar HM; Hancioglu B; Yu L; Jin M; Ogata Y; Hart PA; Cruz-Monserrate Z; Lesinski GB; Conwell DL
• The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
  Mol Cancer Ther Volume: 16 Page(s): 417 - 427
  03/01/2017 Authors: Farren MR; Hennessey RC; Shakya R; Elnaggar O; Young G; Kendra K; Landesman Y; Elloul S; Crochiere M; Klebanov B
• Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
  Mol Cancer Ther Volume: 16 Page(s): 344 - 356
  02/01/2017 Authors: Talbert EE; Yang J; Mace TA; Farren MR; Farris AB; Young GS; Elnaggar O; Che Z; Timmers CD; Rajasekera P
• A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN--2b in patients with CEA-expressing carcinomas.
  Cancer Immunol Immunother Volume: 65 Page(s): 1353 - 1364
  11/01/2016 Authors: Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T
• Inhibition of Jak/STAT Signaling Limits the Activation of Pancreatic Stellate Cells In Vitro and Cerulein-Induced Pancreatitis In Vivo
  Volume: 45 Page(s): 1517 - 1517
  11/01/2016 Authors: Komar H; Mace T; Serpa G; Elnaggar O; Conwell DL; Hart P; Schmidt C; Dillhoff M; Ming J; Lesinski G
• Laser Capture Microdissection and Proteomic Characterization of Acinar Cells From Cerulein Treated Mice Reveals Significant Up-Regulation of Cytoskeletal Proteins
  Volume: 45 Page(s): 1537 - 1537
  11/01/2016 Authors: Shapiro JP; Komar H; Hancioglu B; Yu L; Hart P; Cruz-Monserrate Z; Conwell DL; Lesinski G
• Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia.
  Neoplasia Volume: 18 Page(s): 541 - 552
  09/01/2016 Authors: Pitarresi JR; Liu X; Sharma SM; Cuitio MC; Kladney RD; Mace TA; Donohue S; Nayak SG; Qu C; Lee J
• Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia.
  Genes Dev Volume: 30 Page(s): 1943 - 1955
  09/01/2016 Authors: Liu X; Pitarresi JR; Cuitio MC; Kladney RD; Woelke SA; Sizemore GM; Nayak SG; Egriboz O; Schweickert PG; Yu L
• Endoscopic Pancreas Fluid Collection: Methods and Relevance for Clinical Care and Translational Science.
  Am J Gastroenterol Volume: 111 Page(s): 1258 - 1266
  09/01/2016 Authors: Hart PA; Topazian M; Raimondo M; Cruz-Monserrate Z; Fisher WE; Lesinski GB; Steen H; Conwell DL
• Defining the role of PAK7 variants in melanoma
  Volume: 76
  07/01/2016 Authors: Lapak KM; Gross MA; Vroom DC; Lesinski GB; Carson WE
• Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma
  Volume: 76
  07/01/2016 Authors: Farren MR; Shakya R; Hennessey R; Mace T; Yang J; Elnaggar O; Young G; Landesman Y; Carlson R; Elloul S
• Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
  Mol Ther Volume: 24 Page(s): 1150 - 1158
  06/01/2016 Authors: Noonan AM; Farren MR; Geyer SM; Huang Y; Tahiri S; Ahn D; Mikhail S; Ciombor KK; Pant S; Aparo S
• Systemic Immune Activity Predicts Overall Survival in Treatment-Nave Patients with Metastatic Pancreatic Cancer.
  Clin Cancer Res Volume: 22 Page(s): 2565 - 2574
  05/15/2016 Authors: Farren MR; Mace TA; Geyer S; Mikhail S; Wu C; Ciombor K; Tahiri S; Ahn D; Noonan AM; Villalona-Calero M
• Stellate cells as mediators of immune suppressive features in pancreatic cancer
  Volume: 196
  05/01/2016 Authors: McQuinn CW; Mace TA; Farren MR; Komar H; Kitano M; Yu L; Bloomston M; Zhong X; Zimmers T; Bekaii-Saab T
• Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
  Oncotarget Volume: 7 Page(s): 5306 - 5312
  02/02/2016 Authors: Ahn DH; Ozer HG; Hancioglu B; Lesinski GB; Timmers C; Bekaii-Saab T
• Whole-exome tumor sequencing study in patients with biliary cancer with a response to MEK inhibitors.
  Volume: 34
  02/01/2016 Authors: Ahn DH; Ozer HG; Hancioglu B; Lesinski GB; Timmers CD; Bekaii-Saab TS
• Differential Expression of microRNA in Human Pancreatic Fibroblasts and Pancreatic Cancer-Associated Stellate Cells
  Volume: 23 Page(s): S24 - S24
  02/01/2016 Authors: Kitano M; Chen JL; Mace TA; Farren MR; Komar HM; Bekaii-Saab T; Schmidt CR; Bloomston M; Lesinski GB
• Comprehensive analysis of radiographic, clinical, and inflammatory markers demonstrating changes in lean muscle correlate with outcome in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT).
  Volume: 34
  02/01/2016 Authors: Ahn DH; Ahn C; Nagar V; Noonan AM; Farren M; Lesinski GB; Knopp MV; Bekaii-Saab TS
• MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.
  Onco Targets Ther Volume: 9 Page(s): 5931 - 5941
  01/01/2016 Authors: Markowitz J; Abrams Z; Jacob NK; Zhang X; Hassani JN; Latchana N; Wei L; Regan KE; Brooks TR; Uppati SR
• Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
  Oncotarget Volume: 6 Page(s): 44509 - 44522
  12/29/2015 Authors: Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T
• Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
  J Natl Cancer Inst Volume: 107 Page(s): djv274
  12/01/2015 Authors: Tseng Y-C; Kulp SK; Lai I-L; Hsu E-C; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB
• Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.
  Cancer Prev Res (Phila) Volume: 8 Page(s): 1036 - 1044
  11/01/2015 Authors: Lesinski GB; Reville PK; Mace TA; Young GS; Ahn-Jarvis J; Thomas-Ahner J; Vodovotz Y; Ameen Z; Grainger E; Riedl K
• Jak2/STAT3 Inhibition Limits the Activation of Pancreatic Stellate Cells InVitro
  Volume: 44 Page(s): 1388 - 1388
  11/01/2015 Authors: Komar HM; Serpa G; Mace T; Elnaggar O; Bloomston M; Conwell DL; Lesinski GB
• Proteomic Characterization of Acinar Cells Isolated Using Laser Capture Microdissection From Pancreata of Mice With Cerulein-Induced Chronic Pancreatitis
  Volume: 44 Page(s): 1414 - 1414
  11/01/2015 Authors: Shapiro JP; Komar H; Hart P; Conwell DL; Lesinski GB
• Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
  Cancer Prev Res (Phila) Volume: 8 Page(s): 1045 - 1054
  11/01/2015 Authors: Ahn-Jarvis JH; Clinton SK; Grainger EM; Riedl KM; Schwartz SJ; Lee M-LT; Cruz-Cano R; Young GS; Lesinski GB; Vodovotz Y
• The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
  J Immunol Volume: 195 Page(s): 1995 - 2005
  09/01/2015 Authors: Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC
• Dual targeting of MEK and PI3K pathways can act via tumor-intrinsic mechanisms to overcome resistance and tumor-extrinsic mechanisms to modulate immunity and limit cancer cachexia
  Volume: 75
  08/01/2015 Authors: Yang J; Talbert E; Elnaggar O; Rajasekera P; Mace T; Farren M; Che Z; Swanson B; Young G; Haverick E
• Soy isoflavones and their metabolites modulate IL-12-induced NK cell IFN-gamma production
  Volume: 75
  08/01/2015 Authors: Mace TA; King S; Farren M; McMichael E; Scoville S; Carson WE; Young G; Thomas-Ahner J; Riedl KM; Schwartz S
• Combined inhibition of MEK and PI3K elicits anti-tumor activity in human cholangiocarcinoma
  Volume: 75
  08/01/2015 Authors: Yang J; Elnaggar O; Mace T; Farren M; Young G; Lee P; Keenan K; Che Z; Kaufman J; Guttridge D
• Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
  Cancer Immunol Immunother Volume: 64 Page(s): 727 - 736
  06/01/2015 Authors: Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B
• Optimization of miRNA profiling techniques for melanoma and pancreatic cancer clinical trials.
  Volume: 33
  05/20/2015 Authors: Markowitz J; Abrams Z; Jacob N; Zhang X; Latchana N; Wei L; Brooks TR; Uppati SR; Levine KM; Bekaii-Saab TS
• Correlation of changes in lean muscle weight with outcome in metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT).
  Volume: 33
  05/20/2015 Authors: Ahn DH; Ahn C; Nagar V; Farren M; Lesinski GB; Knopp MV; Bekaii-Saab TS
• Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial.
  Mol Nutr Food Res Volume: 59 Page(s): 658 - 669
  04/01/2015 Authors: Cooperstone JL; Ralston RA; Riedl KM; Haufe TC; Schweiggert RM; King SA; Timmers CD; Francis DM; Lesinski GB; Clinton SK
• Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.
  Cancer Immunol Immunother Volume: 64 Page(s): 149 - 159
  02/01/2015 Authors: Markowitz J; Brooks TR; Duggan MC; Paul BK; Pan X; Wei L; Abrams Z; Luedke E; Lesinski GB; Mundy-Bosse B
• Intestinal microbial dysbiosis and colonic epithelial cell hyperproliferation by dietary -mangostin is independent of mouse strain.
  Nutrients Volume: 7 Page(s): 764 - 784
  01/22/2015 Authors: Gutierrez-Orozco F; Thomas-Ahner JM; Galley JD; Bailey MT; Clinton SK; Lesinski GB; Failla ML
• A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
  Clin Cancer Res Volume: 20 Page(s): 5946 - 5955
  12/01/2014 Authors: Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR
• STAT3 inhibitors elicit direct anti-tumor effects against human biliary caner cell lines and limit release of immune suppressive cytokines in vitro
  Volume: 74
  10/01/2014 Authors: Yang J; Keenan K; Mace T; Bekaii-Saab T; Fuchs J; Schwartz E; Li C; Lin J; Li P-K; Lesinski G
• Bioactive compounds or metabolites from black raspberries modulate T lymphocyte function, myeloid cell differentiation and Jak/STATsignaling
  Volume: 74
  10/01/2014 Authors: Mace TA; King S; Ameen Z; Elnaggar O; Young G; Riedl K; Schwartz S; Clinton S; Knobloch T; Weghorst C
• Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling.
  Cancer Immunol Immunother Volume: 63 Page(s): 889 - 900
  09/01/2014 Authors: Mace TA; King SA; Ameen Z; Elnaggar O; Young G; Riedl KM; Schwartz SJ; Clinton SK; Knobloch TJ; Weghorst CM
• A mathematical model for pancreatic cancer growth and treatments.
  J Theor Biol Volume: 351 Page(s): 74 - 82
  06/21/2014 Authors: Louzoun Y; Xue C; Lesinski GB; Friedman A
• Dietary -mangostin, a xanthone from mangosteen fruit, exacerbates experimental colitis and promotes dysbiosis in mice.
  Mol Nutr Food Res Volume: 58 Page(s): 1226 - 1238
  06/01/2014 Authors: Gutierrez-Orozco F; Thomas-Ahner JM; Berman-Booty LD; Galley JD; Chitchumroonchokchai C; Mace T; Suksamrarn S; Bailey MT; Clinton SK; Lesinski GB
• Dietary alpha-mangostin exacerbates colitis and adversely alters the gut microbiota in mice
  Volume: 28
  04/01/2014 Authors: Gutierrez-Orozco F; Thomas-Ahner J; Berman-Booty L; Galley J; Chitchumroonchokchai C; Mace T; Bailey M; Clinton S; Lesinski G; Failla M
• A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
  J Immunother Volume: 37 Page(s): 180 - 186
  04/01/2014 Authors: Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A
• Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
  PLoS One Volume: 9 Page(s): e102983
  01/01/2014 Authors: Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin J-R
• A phase I trial of bortezomib and interferon--2b in metastatic melanoma.
  J Immunother Volume: 37 Page(s): 55 - 62
  01/01/2014 Authors: Markowitz J; Luedke EA; Grignol VP; Hade EM; Paul BK; Mundy-Bosse BL; Brooks TR; Dao T-V; Kondalasula SV; Lesinski GB
• Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells.
  J Surg Res Volume: 184 Page(s): 855 - 860
  10/01/2013 Authors: Mace TA; Collins AL; Wojcik SE; Croce CM; Lesinski GB; Bloomston M
• Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment.
  Oncoimmunology Volume: 2 Page(s): e24891
  07/01/2013 Authors: Mace TA; Bloomston M; Lesinski GB
• The potential for targeting the STAT3 pathway as a novel therapy for melanoma.
  Future Oncol Volume: 9 Page(s): 925 - 927
  07/01/2013 Authors: Lesinski GB
• Bortezomib and interferon alpha-2b in metastatic melanoma.
  Volume: 31
  05/20/2013 Authors: Markowitz J; Luedke EA; Grignol VP; Hade E; Paul BK; Mundy-Bosse BL; Thao-Vi D; Kondalasula V; Lesinski GB; Olencki T
• Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.
  Cancer Res Volume: 73 Page(s): 3007 - 3018
  05/15/2013 Authors: Mace TA; Ameen Z; Collins A; Wojcik S; Mair M; Young GS; Fuchs JR; Eubank TD; Frankel WL; Bekaii-Saab T
• -Mangostin: anti-inflammatory activity and metabolism by human cells.
  J Agric Food Chem Volume: 61 Page(s): 3891 - 3900
  04/24/2013 Authors: Gutierrez-Orozco F; Chitchumroonchokchai C; Lesinski GB; Suksamrarn S; Failla ML
• Novel small molecule CRM1 inhibitors induce nuclear accumulation of p53, phosphorylated ERK and apoptosis in human melanoma cells.
  Volume: 73
  04/15/2013 Authors: Yang J; Bill MA; Young GS; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin J-R; Lesinski G
• An ethanol extract from black raspberries inhibits myeloid cell differentiation, STAT3 phosphorylation and alters T lymphocyte chemotaxis by upregulating CXCR3.
  Volume: 73
  04/15/2013 Authors: Mace TA; Ameen Z; Weghorst CM; Knobloch TJ; Lesinski GB
• Reduced pro-inflammatory cytokines and immunosuppressive cells in patients with prostate cancer following consumption of soy isoflavone enriched bread.
  Volume: 73
  04/15/2013 Authors: Lesinski GB; Mace TA; Reville P; Ahn-Jarvis J; Bill M; Nicholas C; Vodovotz Y; Grainger E; Riedl K; Young G
• Immune-suppressive myeloid cells are induced during disease progression in patients with advanced pancreatic adenocarcinoma
  Volume: 73
  04/15/2013 Authors: Markowitz J; Paul BK; Brooks TR; Wei L; Pan J; Martin KL; Luedke E; Mundy-Bosse BL; Lesinski GB; Bekaii-Saab T
• MEK162, an allosteric MEK inhibitor promotes apoptosis and in vivo antitumor activity against human binary cancer cell lines
  Volume: 73
  04/15/2013 Authors: Yang J; Mace TA; Young GS; Lee PA; Keenan KE; Che Z; Bekaii-saab T; Lesinski GB
• Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.
  Volume: 73
  04/15/2013 Authors: Mace TA; Ameen Z; Frankel W; Collins A; Wojcik S; Mair M; Young GS; Fuchs JR; Eubank TD; Bekaii-Saab T
• Anti-inflammatory activity and metabolism of alpha-mangostin by cells of human origin
  Volume: 27
  04/01/2013 Authors: Gutierrez-Orozco F; Chitchumroonchokchai C; Lesinski GB; Failla ML
• Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.
  Blood Volume: 121 Page(s): 351 - 359
  01/10/2013 Authors: Gaudio E; Paduano F; Ngankeu A; Lovat F; Fabbri M; Sun H-L; Gasparini P; Efanov A; Peng Y; Zanesi N
• PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
  PLoS One Volume: 8 Page(s): e74710
  01/01/2013 Authors: Nicholas C; Yang J; Peters SB; Bill MA; Baiocchi RA; Yan F; Sf S; Tae S; Gaudio E; Wu X
• Pancreatic Cancer Associated Stellate Cells Differentiate Immune Cells into an Immunosuppressive Phenotype
  Volume: 35 Page(s): 787 - 788
  11/01/2012 Authors: Mace TA; Ameen Z; Collins A; Wojcik S; Mair M; Bekaii-Saab T; Bloomston M; Lesinski GB
• PRMT5 is upregulated in malignant and metastatic melanoma, and regulates expression of the MITF transcription factor
  Volume: 72
  04/15/2012 Authors: Nicholas C; Yang J; Peters SB; Baiocchi RA; Yan F; Sif S; Tae S; Young GS; Greyer MR; Lesinski GB
• UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion.
  J Invest Dermatol Volume: 132 Page(s): 695 - 702
  03/01/2012 Authors: Sullivan NJ; Tober KL; Burns EM; Schick JS; Riggenbach JA; Mace TA; Bill MA; Young GS; Oberyszyn TM; Lesinski GB
• Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
  PLoS One Volume: 7 Page(s): e40724
  01/01/2012 Authors: Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J
• -Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.
  Cancer Epidemiol Biomarkers Prev Volume: 20 Page(s): 2273 - 2279
  10/01/2011 Authors: Lemeshow S; Srensen HT; Phillips G; Yang EV; Antonsen S; Riis AH; Lesinski GB; Jackson R; Glaser R
• miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.
  Br J Cancer Volume: 105 Page(s): 1023 - 1029
  09/27/2011 Authors: Grignol V; Fairchild ET; Zimmerer JM; Lesinski GB; Walker MJ; Magro CM; Kacher JE; Karpa VI; Clark J; Nuovo G
• Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4 and CD8 T cells.
  Cancer Immunol Immunother Volume: 60 Page(s): 1281 - 1288
  09/01/2011 Authors: Guenterberg KD; Lesinski GB; Mundy-Bosse BL; Karpa VI; Jaime-Ramirez AC; Wei L; Carson WE
• Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 T cells from patients with GI malignancy.
  Cancer Immunol Immunother Volume: 60 Page(s): 1269 - 1279
  09/01/2011 Authors: Mundy-Bosse BL; Young GS; Bauer T; Binkley E; Bloomston M; Bill MA; Bekaii-Saab T; Carson WE; Lesinski GB
• Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
  Cancer Res Volume: 71 Page(s): 5101 - 5110
  08/01/2011 Authors: Mundy-Bosse BL; Lesinski GB; Jaime-Ramirez AC; Benninger K; Khan M; Kuppusamy P; Guenterberg K; Kondadasula SV; Chaudhury AR; La Perle KM
• Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment.
  J Control Release Volume: 151 Page(s): 239 - 245
  05/10/2011 Authors: He H; Grignol V; Karpa V; Yen C; LaPerle K; Zhang X; Jones NB; Liang MI; Lesinski GB; Ho WSW
• Immunomodulatory cytokines as therapeutic agents for melanoma.
  Immunotherapy Volume: 3 Page(s): 673 - 690
  05/01/2011 Authors: Nicholas C; Lesinski GB
• Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signal transduction in wD4(+) T cells from patients with gastrointestinal malignancy
  Volume: 71
  04/15/2011 Authors: Mundy BL; Young GS; Bauer T; Binkley E; Bloomston M; Bill MA; Bekaii-Saab T; Carson WE; Lesinski GB
• The expression of PRMT5 methyltransferase mediates cell survival and metastatic phenotype in malignant melanoma
  Volume: 71
  04/15/2011 Authors: Nicholas C; Yan F; Peters SB; Bill MA; Li P-K; Li C; Fuchs JR; Baiocchi R; Lesinski GB
• Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signal transduction in CD4(+) T cells from patients with gastrointestinal malignancy
  Volume: 71
  04/15/2011 Authors: Mundy BL; Young GS; Bauer T; Binkley E; Bloomston M; Bill MA; Bekaii-Saab T; Carson WE; Lesinski GB
• Sex differences in UVB-induced cutaneous tumor development in Skh-1 mice following topical antioxidant/anti-inflammatory treatment
  Volume: 131 Page(s): S116 - S116
  04/01/2011 Authors: Burns EM; Tober KL; Sullivan NJ; Schick JS; Riggenbach JA; Young GS; Lesinski GB; Oberyszyn TM
• Catalase potentiates a sex discrepancy in myeloid-derived suppressor cell expansion in a mouse model of ultraviolet light-induced skin cancer
  Volume: 131 Page(s): S20 - S20
  04/01/2011 Authors: Sullivan NJ; Tober KL; Burns E; Schick J; Riggenbach J; Bill M; Young G; Oberyszyn TM; Lesinski GB
• Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma
  Volume: 29
  03/01/2011 Authors: Lam ET; Lesinski G; Mortazavi A; Kendra KL; Carson WE; Tahiri S; Liersemann R; Clinton SK; Olencki T; Monk JP
• Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma.
  J Clin Oncol Volume: 29 Page(s): 337
  03/01/2011 Authors: Lam ET; Lesinski G; Mortazavi A; Kendra KL; Carson WE; Tahiri S; Liersemann R; Clinton SK; Olencki T; Monk JP
• Myeloid-derived Suppressor Cells and Decreased Interferon Responsiveness in Tumor-Bearing Mice
  Volume: 33 Page(s): 887 - 887
  10/01/2010 Authors: Mundy BL; Lesinski G; Benninger K; Khan M; Kuppusamy P; Guenterberg K; Kondadasula SV; Chaudhury AR; Kreiner M; Young G
• IL-6 and IL-10 are Correlated with Distinct MDSC Profiles in Patients with Gastrointestinal Malignancy
  Volume: 33 Page(s): 872 - 872
  10/01/2010 Authors: Lesinski GB; Mundy BL; Young GS; Bauer T; Binkley E; Bloomston M; Carson WE; Bekaii-Saab T
• Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.
  J Immunother Volume: 33 Page(s): 659 - 662
  09/01/2010 Authors: Lesinski GB; Carson WE; Repasky EA; Wei W-Z; Kalinski P; Lotze MT; June CH; Petros W; Muthusamy N; Olencki T
• A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
  Mol Cancer Volume: 9 Page(s): 217
  08/16/2010 Authors: Lin L; Deangelis S; Foust E; Fuchs J; Li C; Li P-K; Schwartz EB; Lesinski GB; Benson D; L J
• The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
  Mol Cancer Volume: 9 Page(s): 165
  06/25/2010 Authors: Bill MA; Fuchs JR; Li C; Yui J; Bakan C; Benson DM; Schwartz EB; Abdelhamid D; Lin J; Hoyt DG
• A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
  Cancer Chemother Pharmacol Volume: 66 Page(s): 151 - 158
  05/01/2010 Authors: Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D
• Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.
  BMC Cancer Volume: 10 Page(s): 142
  04/14/2010 Authors: Lesinski GB; Zimmerer JM; Kreiner M; Trefry J; Bill MA; Young GS; Becknell B; Carson WE
• Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
  Mol Cancer Ther Volume: 9 Page(s): 510 - 520
  02/01/2010 Authors: Guenterberg KD; Grignol VP; Raig ET; Zimmerer JM; Chan AN; Blaskovits FM; Young GS; Nuovo GJ; Mundy BL; Lesinski GB
• Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
  Cancer Immunol Immunother Volume: 58 Page(s): 2031 - 2037
  12/01/2009 Authors: Lesinski GB; Benninger K; Kreiner M; Quimper M; Young G; Carson WE
• Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.
  Volume: 114 Page(s): 675 - 675
  11/20/2009 Authors: Alinari L; Christian B; Yu B; Shin J; Hertlein EK; Lapalombella R; Yan F; Lesinski G; Zhang X; Lozanski G
• STAT3-specific Small-molecule Curcumin Analogs FLLL32 and FLLL62 Induce Apoptosis and Enhance the Direct Antitumor Effect of Interferons
  Volume: 32 Page(s): 1005 - 1005
  11/01/2009 Authors: Bill MA; Fuchs JR; Li C; Schwartz EB; Lin J; Hoyt DG; Foor B; Otterson D; Yui J; Carson WE
• Small-molecule Curcumin Analogs Induce Apoptosis in Human Melanoma Cells via STAT3 Inhibition but Do Not Alter the Cellular Response to Immunotherapeutic Cytokines
  Volume: 32 Page(s): 1005 - 1005
  11/01/2009 Authors: Lesinski GB; Bill MA; Fuchs JR; Li C; Bakan C; Benson DM; Schwartz EB; Lin J; Fossey SL; Young GS
• Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.
  Mol Cancer Ther Volume: 8 Page(s): 2726 - 2735
  09/01/2009 Authors: Bill MA; Bakan C; Benson DM; Fuchs J; Young G; Lesinski GB
• The small molecule curcumin analog FLLL-32 induces apoptosis in human melanoma cells via STAT3 inhibition and elicits in vivo anti-tumor activity.
  Volume: 69
  05/01/2009 Authors: Lesinski G; Bill M; Li C; Fuchs J; Kulp S; Ihnat M; Lin J; Hoyt D; Young G; Carson W
• A novel small molecule exhibits potent growth suppressive activity through the inhibition of constitutive JAK2/STAT3 signaling in breast cancer, pancreatic cancer, and glioblastoma cells
  Volume: 69
  05/01/2009 Authors: Lin L; Hutzen B; Ball S; Foust E; DeAngelis S; Zuo M; Peng Z; Li C; Fuchs J; Li P-K
• A NOVEL SMALL MOLECULE EXHIBITS POTENT GROWTH SUPPRESSIVE ACTIVITY THROUGH THE INHIBITION OF CONSTITUTIVE JAK2/STAT3 SIGNALING IN HUMAN CANCER CELLS
  Volume: 20 Page(s): 20 - 20
  05/01/2009 Authors: Lin J; Lin L; Hutzen B; Ball S; Zuo M; Foust E; DeAngelis S; Wei CC; Peng Z; Li C
• IL-29 Induces Jak-STAT Signal Transduction and can Synergize With Temozolomide and Bortezomib in Human Melanoma Cell Lines
  Volume: 31 Page(s): 929 - 929
  11/01/2008 Authors: Guenterberg K; Raig E; Zimmerer J; Lesinski G; Carson W
• IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
  Cancer Res Volume: 68 Page(s): 8351 - 8360
  10/15/2008 Authors: Lesinski GB; Raig ET; Guenterberg K; Brown L; Go MR; Shah NN; Lewis A; Quimper M; Hade E; Young G
• Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
  Clin Cancer Res Volume: 14 Page(s): 5900 - 5906
  09/15/2008 Authors: Zimmerer JM; Lesinski GB; Ruppert AS; Radmacher MD; Noble C; Kendra K; Walker MJ; Carson WE
• VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
  J Interferon Cytokine Res Volume: 28 Page(s): 553 - 561
  09/01/2008 Authors: Raig ET; Jones NB; Varker KA; Benniger K; Go MR; Biber JL; Lesinski GB; Carson WE
• Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
  Cancer Immunol Immunother Volume: 57 Page(s): 1137 - 1149
  08/01/2008 Authors: Kondadasula SV; Varker KA; Lesinski GB; Benson DM; Lehman A; Olencki T; Monk JP; Kendra K; Carson WE
• A phase I study of bortezomib and interferon-alpha-2b in patients with metastatic melanoma
  Volume: 26
  05/20/2008 Authors: Kendra KL; Lesinski GB; Olencki TE; Carson W
• Micro-RNA-21 and micro-RNA-155 as predictors of a malignant phenotype in melanocytic lesions
  Volume: 26
  05/20/2008 Authors: Lesinski GB; Raig ET; Zimmerer JM; Karpa V; Nuovo G; Lehman A; Peters S; Kacher JE; Magro CM; Croce CM
• STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha.
  Cancer Immunol Immunother Volume: 56 Page(s): 1845 - 1852
  11/01/2007 Authors: Zimmerer JM; Lesinski GB; Radmacher MD; Ruppert A; Carson WE
• Interferon-alpha-2b induced signal transduction and gene regulation in patient immune cells is not enhanced by a dose increase from 5 MU/m(2) to 10 MU/m(2)
  Volume: 30 Page(s): 876 - 876
  11/01/2007 Authors: Lesinski GB; Zimmerer JM; Lehman A; Ruppert A; Olencki T; Kendra K; Walker MJ; Carson WE
• Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: Analysis via dual parameter flow cytometric assay
  Volume: 30 Page(s): 875 - 875
  11/01/2007 Authors: Kondadasula SV; Varker KA; Lesinski GB; Benson DM; Lehman A; Olencki T; Monk P; Kendra K; Carson WE
• The RAF kinase inhibitor sorafenib inhibits JAK-STAT signal transduction in human immune cells
  Volume: 30 Page(s): 872 - 872
  11/01/2007 Authors: Raig ET; Kondadasula SV; Olencki T; Monk JP; Lesinski GB; Carson WE
• Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
  Clin Cancer Res Volume: 13 Page(s): 5010 - 5019
  09/01/2007 Authors: Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR
• A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
  Ann Surg Oncol Volume: 14 Page(s): 2367 - 2376
  08/01/2007 Authors: Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX
• IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
  J Immunol Volume: 178 Page(s): 4832 - 4845
  04/15/2007 Authors: Zimmerer JM; Lesinski GB; Kondadasula SV; Karpa VI; Lehman A; Raychaudhury A; Becknell B; Carson WE
• Use of nanochannel membranes to regulate the release of cytokines from biodegradable reservoirs
  Volume: 14 Page(s): 112 - 112
  02/01/2007 Authors: Jones NB; Lesinski G; Lee LJ; He H; Ferrari M; Carson WE
• Suppressors of cytokine signaling (SOCS) proteins regulate the responsiveness of melanoma cells to interferon
  Volume: 29 Page(s): 640 - 640
  11/01/2006 Authors: Lesinski GB; Zimmerer JM; Trefry J; Kondadasula SV; Brasdovich M; Becknell B; Carson WE
• IFN-alpha-induced signal transduction, gene expression, and anti-tumor activity of immune effector cells are negatively regulated by suppressors of cytokine signaling proteins
  Volume: 29 Page(s): 642 - 643
  11/01/2006 Authors: Zimmerer JM; Lesinski GB; Kondadasula SV; Lehman A; RayChaudhury A; Carson WE
• Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
  Clin Cancer Res Volume: 12 Page(s): 5850 - 5858
  10/01/2006 Authors: Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
• TGF-beta inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-gamma).
  Am J Transplant Volume: 6 Page(s): 1809 - 1819
  08/01/2006 Authors: VanBuskirk AM; Lesinski GB; Nye KJ; Carson WE; Yee LD
• Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
  Surgery Volume: 140 Page(s): 297 - 306
  08/01/2006 Authors: Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
• Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects
  Volume: 140 Page(s): 297 - 306
  08/01/2006 Authors: Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
• Melanoma cells are less responsive to interferon-induced signal transduction when compared to immune effector cells: A role for the Suppressors of Cytokine Signaling (SOCS) proteins
  Volume: 66
  04/01/2006 Authors: Lesinski GB; Zimmerer JM; Trefry J; Sackey K; Crespin T; Kondadasula SV; Becknell B; Raychaudhury A; Walker MJ; Carson WE
• Suppressors of cytokine signaling proteins 1 and 3 regulate the immune response to interferon-alpha.
  Volume: 66
  04/01/2006 Authors: Zimmerer JM; Lesinski GB; Kondadasula SV; Becknell B; Carson WE
• Multiparametric flow cytometric analysis of immune cell subset response to Interleukin-2 (IL-2) immunotherapy
  Volume: 66
  04/01/2006 Authors: Varker KA; Kondadasula SV; Go MR; Lesinski GB; Lehman A; Monk JP; Kendra K; Carson WE
• Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
  J Clin Oncol Volume: 23 Page(s): 8835 - 8844
  12/01/2005 Authors: Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M
• Enhanced in vitro and in vivo anti-tumor activity of bortezomib (Velcadeo (R), PS-341) when administered with interferon-alpha
  Volume: 28 Page(s): 622 - 623
  11/01/2005 Authors: Lesinski GB; Shah NN; Raig E; Hade E; Brown L; Lewis A; Go MR; Bouchard P; Carson WE
• Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
  Cancer Immunol Immunother Volume: 54 Page(s): 815 - 825
  09/01/2005 Authors: Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
• A role for antigen presenting cells (APC) in post-transplant lymphoproliferative disorder (PTLD).
  Volume: 5 Page(s): 418 - 418
  05/01/2005 Authors: VanBuskirk AM; Nye KJ; Lesinski G; Yee LD; Carson WE
• Release of biologically functional interferon-alpha from a nanochannel delivery system.
  Biomed Microdevices Volume: 7 Page(s): 71 - 79
  03/01/2005 Authors: Lesinski GB; Sharma S; Varker KA; Sinha P; Ferrari M; Carson WE
• A novel flow cytometric assay for measurement of phosphorylated STAT5 in peripheral blood mommuclear cells of melanoma patients receiving interleukin-2
  Volume: 12 Page(s): S42 - S42
  02/01/2005 Authors: Varker KA; Go MR; Lesinski GB; Kondadasula SV; Monk JP; Carson WE
• Flow cytometric monitoring of Jak-STAT signal transduction within melanoma cells
  Volume: 27 Page(s): S42 - S42
  11/01/2004 Authors: Lesinski G; Sackey K; Kondadasula SV; Walker M; Carson W
• Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
  J Natl Cancer Inst Volume: 96 Page(s): 1331 - 1342
  09/01/2004 Authors: Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
• IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
  J Immunol Volume: 172 Page(s): 7368 - 7376
  06/15/2004 Authors: Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
• Expression of pro-angiogenic factors in malignant melanoma and their regulation by low-dose interferon-alpha
  Volume: 11 Page(s): S122 - S122
  02/01/2004 Authors: Go M; Biber J; Lesinski GB; Carson WE
• The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
  Volume: 116 Page(s): 129 - 136
  01/01/2004 Authors: Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
• VELCADE potentiates the anti-tumor activity of interferon-alpha in vitro and in a murine model of malignant melanoma.
  Volume: 9 Page(s): 6252S - 6253S
  12/01/2003 Authors: Lesinski GB; Shah NN; Go M; Bouchard P; Carson WE
• Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to IFN-alpha adjuvant therapy
  Volume: 26 Page(s): S40 - S41
  11/01/2003 Authors: Lesinski G; Valentino D; Chaudhury AR; Walker M; Carson W
• The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
  J Clin Invest Volume: 112 Page(s): 170 - 180
  07/01/2003 Authors: Lesinski GB; Anghelina M; Zimmerer J; Bakalakos T; Badgwell B; Parihar R; Hu Y; Becknell B; Abood G; Chaudhury AR
• Vaccines against polysaccharide antigens.
  Curr Drug Targets Infect Disord Volume: 1 Page(s): 325 - 334
  11/01/2001 Authors: Lesinski GB; Westerink MA
• Novel vaccine strategies to T-independent antigens.
  J Microbiol Methods Volume: 47 Page(s): 135 - 149
  11/01/2001 Authors: Lesinski GB; Westerink MA
• A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice.
  Vaccine Volume: 19 Page(s): 1717 - 1726
  02/08/2001 Authors: Lesinski GB; Smithson SL; Srivastava N; Chen D; Widera G; Westerink MA